{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:03:49Z","timestamp":1784527429748,"version":"3.55.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Cognitive impairment increasingly emerges at the intersection of type 2 diabetes mellitus, vascular brain injury, chronic kidney disease, heart failure, and neurodegeneration, prompting interest in therapies that modify shared metabolic and inflammatory drivers of brain vulnerability. Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor widely used in type 2 diabetes and cardiorenal disease, has attracted attention as a candidate modulator of cognitive decline because its established peripheral pharmacology extends beyond glucose lowering to include natriuresis, blood pressure reduction, weight loss, improved insulin resistance, reduced oxidative and inflammatory stress, and favorable cardiorenal effects. In this review, we examine the pharmacological basis by which these systemic actions could influence the neurovascular unit, mitochondrial homeostasis, glial activation, autophagy-related signaling, and synaptic plasticity pathways implicated in cognitive impairment. We summarize preclinical evidence suggesting that dapagliflozin can improve cognitive performance and modulate pathways such as AMPK-mTOR, Wnt\/\u03b2-catenin, CREB\/BDNF, oxidative stress responses, and neuroinflammatory signaling in experimental models, while also critically evaluating the limitations of these models. We then assess the current human evidence, distinguishing observational studies that suggest lower dementia risk from randomized clinical evidence that has not yet established a definitive cognition-related benefit. We argue that dapagliflozin should currently be viewed not as a proven cognitive therapeutic, but as a mechanistically plausible metabolic-neurovascular intervention whose relevance may be greatest in metabolically vulnerable phenotypes. Finally, we outline key translational challenges, including uncertainty regarding direct central target engagement, the need for biomarker-enriched trial designs, and the importance of integrating pharmacological, vascular, and neurodegenerative frameworks in future studies.<\/jats:p>","DOI":"10.3389\/fphar.2026.1895764","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:36:01Z","timestamp":1784525761000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dapagliflozin and cognitive impairment: pharmacological mechanisms, translational evidence, and future directions"],"prefix":"10.3389","volume":"17","author":[{"given":"Ahmad H.","family":"Alhowail","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University","place":["Buraydah, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s11064-025-04538-0","article-title":"Dapagliflozin ameliorates doxorubicin-induced chemobrain and cognitive abnormalities in rats: modulation of AKT\/GSK-3\u03b2 and Wnt\/\u03b2-catenin pathways","volume":"50","author":"Abdelhafez","year":"2025","journal-title":"Neurochem. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41574-018-0048-7","article-title":"Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications","volume":"14","author":"Biessels","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e70416","DOI":"10.1002\/alz.70416","article-title":"Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: a randomized controlled trial","volume":"21","author":"Burns","year":"2025","journal-title":"Alzheimers Dement."},{"key":"B6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/archneurol.2009.27","article-title":"The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged","volume":"66","author":"Craft","year":"2009","journal-title":"Arch. Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/db13-1954","article-title":"Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease","volume":"63","author":"De Felice","year":"2014","journal-title":"Diabetes"},{"key":"B8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/CIRCRESAHA.116.308426","article-title":"Vascular cognitive impairment","volume":"120","author":"Dichgans","year":"2017","journal-title":"Circ. Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"668614","DOI":"10.3389\/fnagi.2021.668614","article-title":"The significance of vascular pathogenesis in the examination of corticobasal syndrome","volume":"13","author":"Dunalska","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.brainresbull.2022.01.017","article-title":"Dapagliflozin diminishes memory and cognition impairment in streptozotocin-induced diabetes through its effect on Wnt\/\u03b2-catenin and CREB pathway","volume":"181","author":"El-Safty","year":"2022","journal-title":"Brain Res. Bull."},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose cotransporters and their inhibition: clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","article-title":"The probabilistic model of Alzheimer disease: the amyloid hypothesis revised","volume":"23","author":"Frisoni","year":"2022","journal-title":"Nat. Rev. Neurosci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s40120-025-00832-9","article-title":"SGLT-2 inhibitors in the prevention and progression of neurodegenerative diseases: a narrative review","volume":"14","author":"Kostrzewska","year":"2025","journal-title":"Neurol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","article-title":"Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission","volume":"404","author":"Livingston","year":"2024","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.cmet.2018.05.011","article-title":"Hallmarks of brain aging: adaptive and pathological modification by metabolic states","volume":"27","author":"Mattson","year":"2018","journal-title":"Cell Metab."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-005-1762-7","article-title":"Brain glucose metabolism in the early and specific diagnosis of Alzheimer disease","volume":"32","author":"Mosconi","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"B22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000543533","article-title":"The impact of SGLT2 inhibitors on dementia onset in patients with type 2 diabetes: a meta-analysis of cohort studies","volume":"115","author":"Pan","year":"2025","journal-title":"Neuroendocrinology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7434","DOI":"10.3390\/molecules26237434","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"333","author":"Sa-Nguanmoo","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/ph16050753","article-title":"Dapagliflozin ameliorates cognitive impairment in aluminum-chloride-induced Alzheimer's disease via modulation of AMPK\/mTOR, oxidative stress and glucose metabolism","volume":"16","author":"Samman","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jamaneurol.2025.0360","article-title":"Cardioprotective glucose-lowering agents and dementia risk: a systematic review and meta-analysis","volume":"82","author":"Seminer","year":"2025","journal-title":"JAMA Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e079475","DOI":"10.1136\/bmj-2024-079475","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors in adults with type 2 diabetes aged 40\u201369 years: population based cohort study","volume":"386","author":"Shin","year":"2024","journal-title":"BMJ"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1695075","DOI":"10.3389\/fendo.2025.1695075","article-title":"Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: a systematic review and meta-analysis","volume":"16","author":"Song","year":"2025","journal-title":"Front. Endocrinol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3233\/JAD-170585","article-title":"Mitochondria and mitochondrial cascades in Alzheimer disease","volume":"62","author":"Swerdlow","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomized controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"B37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S2213-8587(19)30405-X","article-title":"Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression","volume":"8","author":"van Sloten","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S1474-4422(19)30079-1","article-title":"Small vessel disease: mechanisms and clinical implications","volume":"18","author":"Wardlaw","year":"2019","journal-title":"Lancet Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13195-025-01929-x","article-title":"Comparative dementia risk with GLP-1 receptor agonists, SGLT2 inhibitors and DPP-4 inhibitors in type 2 diabetes: a population-based cohort study","volume":"17","author":"Wu","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"154265","DOI":"10.1016\/j.metabol.2020.154265","article-title":"Impact of antidiabetic agents on dementia risk: a Bayesian network meta-analysis","volume":"109","author":"Zhou","year":"2020","journal-title":"Metabolism"},{"key":"B43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer disease and other disorders","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat. Rev. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1895764\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:36:02Z","timestamp":1784525762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1895764\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":43,"alternative-id":["10.3389\/fphar.2026.1895764"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1895764","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"article-number":"1895764"}}